References
- Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor a monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis. Arthritis Rheum 2005;52:548–53.
- Lovell DJ, Giannini EH, Andreas Reiff PH, Cawkwell GD, Silverman ED, Nocton JJ, et al. (For the Pediatric Rheumatology Collaborative Study Group). Etanercept in children with polyar-ticular juvenile rheumatoid arthritis. N Engl J Med 2000;342: 763–9.
- Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.
- Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimerical monoclonal antibody to tumor necrosis factor a versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.
- Yazici Y, Erkan D. Do etanercept naïve patients respond better to infliximab than RA patients who have failed ETA? Ann Rheum Dis 2004;63:607–8.
- Brocq 0, Plubel Y, Breuil V, Grisot C, Flory P, Mousnier A, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFa. Presse Med 2002;31: 1836–9.
- van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treat-ment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor ablockers can make sense. Ann Rheum Dis 2003;62:1195–8.
- Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar out-comes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J Ftheumatol 2003;30(11): 2315–8.
- Hansen KE, Hildebrand JP, Genovese MC, Cush JJ, Patel S, Cooley DA, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Ftheumatol 2004;31:1098–102.
- Avalli EG, Arreghini M, Amoldi C, Panni B, Marchesoni A, Tosi S, et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Arthritis Rheum 2004;51: 301–2.
- Andersson Gare B, Fasth A, Wiklund I. Measurement of functional status in juvenile chronic arthritis: evaluation of a Swedish version of the childhood health assessment questionnaire. Clin Exp Ftheu-matol 1993;11:569–76.
- Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.
- Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etaner-cept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774–85.
- Takei S, Groh D, Bernstein B, Shaham B, Gallagher K, Reiff A. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Ftheumatol 2001;28:1677–80.
- St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum concentrations to clinical improvement in rheumatoid arthritis: result from ATTRACT: a multicenter, randomized, double-blind, placebo-con-trolled trial. Arthritis Rheum 2004;46:1451–9.